Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
Approval exemplifies commitment to broadening access for patients living with rare diseases globally. Soliris (eculizumab) has been approved in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). Soliris is the first and only complement inhibitor approved for the treatment of NMOSD in China.[1] The approval by the National Medical Products Administration (NMPA) in China was based on results from the Phase III PREVENT trial.[1] In the trial, Soliris met the primary endpoint of prolonging